A phase II study of CCNU with benznidazole for metastatic malignant melanoma

Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1401-3. doi: 10.1016/0360-3016(86)90181-1.

Abstract

The response of 18 patients with metastatic malignant melanoma to the combination of CCNU (130 mg/m2) preceded 3-4 hr earlier by 20 mg/kg of the 2-nitroimidazole benznidazole has been studied. There were four partial and no complete responses in 16 patients evaluable after 1-6 courses. The median response duration was 14 wk (range 5-33) and for static disease 24 wk (range 10-54). Evidence for chemosensitization is equivocal.

MeSH terms

  • Drug Evaluation
  • Drug Synergism
  • Drug Therapy, Combination
  • Humans
  • Lomustine / therapeutic use*
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Nitroimidazoles / therapeutic use*

Substances

  • Nitroimidazoles
  • Lomustine
  • benzonidazole